Tiagabine , 98% , 115103-54-3
CAS NO.:115103-54-3
Empirical Formula: C20H25NO2S2
Molecular Weight: 375.55
MDL number: MFCD00865317
Pack Size | Price | Stock | Quantity |
10mg | RMB553.60 | In Stock |
|
others | Enquire |
PRODUCT Properties
Melting point: | 192oC dec. |
Boiling point: | 568.0±50.0 °C(Predicted) |
Density | 1.208±0.06 g/cm3(Predicted) |
storage temp. | under inert gas (nitrogen or Argon) at 2-8°C |
pka | 3.86±0.20(Predicted) |
Water Solubility | ≥ 13.5mg/mL in Water |
CAS DataBase Reference | 115103-54-3(CAS DataBase Reference) |
Description and Uses
Gabitril was launched in Denmark for use as an add-on therapy in patients refractory to other epilepsy therapies. The compound can be synthesized in five steps beginning with a bis-thiophenyl ketone derivative to produce the (R)-(-)- enantiomer. Its anti-epileptic activity resides in its potent and selective inhibition of GABA synaptosomal uptake. Tiagabine is selective for the GAT-1 GABA transporter in neurons and glia thus enhancing inhibitory GABAergic transmission. Because it has practically no effect on other uptake or receptor systems, it has a reduced potential for neurological side-effects. In particular, it does not have the benzodiazepine-like sedative effects. It is able to cross the blood brain barrier and is considered the most potent GABA uptake inhibitor known.
A GABA uptake inhibitor
Safety
Symbol(GHS) | GHS07 |
Signal word | Warning |
Hazard statements | H315-H319-H335 |
Precautionary statements | P261-P305+P351+P338 |
Hazard Codes | Xi |
Risk Statements | 36/37/38 |
Safety Statements | 26-37/39 |
Hazardous Substances Data | 115103-54-3(Hazardous Substances Data) |